
Ole Audun Werner Haabeth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2947371/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nature Communications, 2011, 2, 240.	12.8	251
2	How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?. Frontiers in Immunology, 2014, 5, 174.	4.8	166
3	mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9153-E9161.	7.1	92
4	Local Delivery of <i>Ox40l</i> , <i>Cd80</i> , and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity. Cancer Research, 2019, 79, 1624-1634.	0.9	85
5	Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an <i>In Situ</i> Inflammatory Immune Response. Cancer Research, 2016, 76, 6864-6876.	0.9	77
6	Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncolmmunology, 2016, 5, e1039763.	4.6	77
7	A model for cancer-suppressive inflammation. Oncolmmunology, 2012, 1, 1146-1155.	4.6	64
8	CD4+ T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs. Cancer Research, 2018, 78, 4573-4585.	0.9	61
9	Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity. Frontiers in Immunology, 2018, 9, 1684.	4.8	52
10	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. Journal of Experimental Medicine, 2020, 217, .	8.5	26
11	Tumors Escape CD4+ T-cell–Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens. Cancer Research, 2015, 75, 3268-3278.	0.9	24
12	Indirect CD4 ⁺ Tâ€cellâ€mediated elimination of MHC II ^{NEG} tumor cells is spatially restricted and fails to prevent escape of antigenâ€negative cells. European Journal of Immunology, 2014, 44, 2625-2637.	2.9	19
13	Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Oncotarget, 2016, 7, 67175-67182.	1.8	18
14	CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages. Blood Advances, 2020, 4, 2595-2605.	5.2	17
15	B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25850-25859.	7.1	15
16	Molecular profiling of tumor-specific T _H 1 cells activated in vivo. OncoImmunology, 2013, 2, e24383.	4.6	13